News on CRISPR, gene editing, RNAi in genetics, genomics, and molecular diagnostics.
The protease-activated Cas9 enzymes could reduce off-target effects and could be used to sense pathogens and trigger an immune response.
GreenLight Biosciences is using a proprietary cell-free RNA production technology to develop RNA-based products for the agricultural market.
The partners will work to find novel proteins, including DNA endonucleases, to develop new gene editing therapies for cystic fibrosis and other diseases.
Ohio State University researchers found that a phosphorothioate-modified DNA-crRNA duplex completely blocked the function of Cas12a.
The firm is developing and beta-testing a line of guide RNA libraries to support CRISPR-based targeted capture and sequencing approaches.
An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.
An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.
In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.
Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.
This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.